Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + sorafenib + cyclophosphamide
- Development stage
- Phase 1
- Lead developer
- St. Jude Children's Research Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Bevacizumab + sorafenib + cyclophosphamide is a combination chemotherapy and targeted therapy regimen being investigated by St. Jude Children's Research Hospital for the treatment of various refractory or recurrent pediatric cancers. The regimen, studied in the Phase I ANGIO1 trial, combines the anti-VEGF monoclonal antibody bevacizumab with the multi-kinase inhibitor sorafenib and low-dose oral cyclophosphamide. This approach aims to synergistically inhibit tumor angiogenesis and growth by targeting the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) pathways while utilizing the cytotoxic and metronomic anti-angiogenic properties of cyclophosphamide. It is primarily indicated for pediatric patients with solid tumors, leukemia, lymphoma, sarcoma, and central nervous system tumors who have failed standard therapies.
- Other names
- Bevacizumab, Sorafenib, and Cyclophosphamide combinationLow-dose cyclophosphamide combination regimen
02
Targets
BRAF (B-Raf proto-oncogene, serine/threonine kinase)DNAFLT3 (Fms related receptor tyrosine kinase 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)RET (Rearranged during transfection receptor tyrosine kinase)RAF1 (c-Raf-1 (Y340D/Y341D))VEGFA (Vascular endothelial growth factor A)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on bevacizumab + sorafenib + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + sorafenib + cyclophosphamide.